Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm

Teva’s planned divestment of non-core assets in order to refocus the company after a troubled first-half has started with a contraceptive device.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Although the strategy may change when Kare Schultz, the newly appointed president and CEO at Teva Pharmaceutical Industries Ltd. settles in, the company’s first divestment of a non-core women’s health asset, the intrauterine copper-releasing device, Paragard, was announced Sept. 11.

The IUD and its Buffalo, NY based manufacturing facility is to be sold to the US-based CooperSurgical Inc. for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By 

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By 

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.